TENAYA THERAPEUTICS INC
NASDAQ: TNYA (Tenaya Therapeutics, Inc.)
Last update: yesterday, 3:08AM0.679
0.01 (1.06%)
| Previous Close | 0.672 |
| Volume | 4,853,683 |
| Price / Sales | 97.15 |
| Price / Book | 2.17 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.15 |
| Total Debt/Equity (MRQ) | 10.81% |
| Current Ratio (MRQ) | 6.68 |
| Operating Cash Flow (TTM) | -84.95 M |
| Levered Free Cash Flow (TTM) | -48.05 M |
| Return on Assets (TTM) | -41.71% |
| Return on Equity (TTM) | -76.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Tenaya Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.13 |
|
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 59.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Burkehill Global Management, Lp | 30 Jun 2026 | 2,000,000 |
| Raiffeisen Bank International Ag | 30 Jun 2026 | 1,200,000 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALI FARAZ | 0.649 | - | 122,000 | 79,178 |
| TINGLEY WHITTEMORE | 0.649 | - | 49,000 | 31,801 |
| Aggregate Net Quantity | 171,000 | |||
| Aggregate Net Value ($) | 110,979 | |||
| Aggregate Avg. Buy ($) | 0.649 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TINGLEY WHITTEMORE | Officer | 10 Sep 2026 | Acquired (+) | 49,000 | 0.649 | 31,801 |
| ALI FARAZ | Officer | 10 Sep 2026 | Acquired (+) | 122,000 | 0.649 | 79,178 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |